Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,401–1,500 of 3,636
Peng, J., Liu, M., Liu, H., Guo, Y., Wu, N., Dong, Q., Qian, J., Dou, K., Zhu, C., & Li, J. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00344-0 · Cited by 11
“Recently, FOURIER trial and ODYSSEY OUTCOMES trial have confirmed that PCSK9 inhibitors reduce major adverse cardiovascular and cerebrovascular events in patients with ASCVD compared with the placebo group [15, 16].”
Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease
Zhao, X., Xu, J., Tang, X., Huang, K., Li, J., Liu, R., Jiang, L., Zhang, Y., Wang, D., Sun, K., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704501 · Cited by 11
“The above studies have shown that the inactivation variation of NPC1L1 can lower the level of LDL-C and reduce the risk of CHD.”
BackgroundInfluentialPharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Hauguel‐Moreau, M., Aïdan, V., Hergault, H., Beauchet, A., Pépin, M., Prati, G., Pillière, R., Ouadahi, M., Josseran, L., Rodon, C., et al. (2022) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.11.005 · Cited by 15
Ying, Q., Ronca, A., Chan, D. C., Pang, J., Favari, E., & Watts, G. F. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13766 · Cited by 9
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Chng, B. L. K., Heng, W. M. P., Soon, Y. M., Hon, J. S., Lau, Y. H., Tan, R. S., & Tan, J. W. C. (2022) · Proceedings of Singapore Healthcare · doi:10.1177/20101058221144115 · Cited by 11
“Both are well tolerated with low rates of adverse drug reactions (ADRs), the most common being local injection site reaction.(5,6) Singapore has a multi-racial population that comprises 75.”
BackgroundMasson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Huerin, M. S., & Nogueira, J. P. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00330-8 · Cited by 11
Is the future of symptomatic intracranial atherosclerotic stenosis management promising?
Liu, D., Liu, J., Cai, Y., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321564 · Cited by 11
Management of dyslipidaemia in patients with comorbidities—facing the challenge
Frühwald, L., Fasching, P., Dobrev, D., Kaski, J. C., Borghi, C., Waßmann, S., Huber, K., Semb, A. G., Agewall, S., & Drexel, H. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae095 · Cited by 11
“2 , 46 , 51 , 62 , 63 , 85 , 88 –90 Lp(a) lowering agents Currently, no drugs are approved for directly lowering Lp(a).”
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 13
Cui, Y., Chen, Y., Li, H., Zhang, W., Wang, X., Xia, M., Gan, N., Zhou, Y., Li, M., Zhang, H., et al. (2025) · Research · doi:10.34133/research.0922 · Cited by 19
“PCSK9 inhibitors have been introduced in clinical practice to lower lipid levels, and trials have demonstrated that these agents can significantly reduce ischemic cardiovascular events in high-risk patients [ 10 , 11 ].”
HDL metabolism and function in diabetes mellitus
Cochran, B. J., King, T. W., Chemello, K., Thomas, S. R., & Rye, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01176-y · Cited by 18
“The monoclonal antibodies evolocumab and alirocumab inhibit PCSK9, increase hepatic levels of LDLR and considerably reduce circulating levels of LDL cholesterol 161,162 .”
Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke
Monguillon, V., Kelly, P. J., O’Donoghue, M. L., Park, J., Bohula, E. A., Saver, J. L., Atar, D., KEECH, A. C., Sever, P., Wang, H., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.077549 · Cited by 14
Raposeiras‐Roubín, S., Assi, E. A., Jiménez-Méndez, C., de la Guía, E. M., Pérez-Rivera, J.-Á., Mangas, M. M., Ayesta, A., Uribarri, A., Jorge‐Pérez, P., Muiños, P. J. A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075388 · Cited by 13
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 12
Sabouret, P. F., Angoulvant, D., Pathak, A., Fysekidis, M., Laterra, G., Costa, F., Angelini, F., Bocchino, P. P., Montalescot, G., & Biondi‐Zoccai, G. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04284-1 · Cited by 11
Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It
Tuka, V., Holub, J., & Bělohlávek, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306210 · Cited by 20
Kato, S., Utsunomiya, D., Horita, N., et al. (2022) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2022.07.004 · Cited by 10
Matsumoto, I., Kurozumi, M., Namba, T., & Takagi, Y. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63607 · Cited by 14
Li, S., Zhang, W., & Liu, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-32209-z · Cited by 15
de Araújo, A. L. V., Santos, R. D., Bittencourt, M. S., Dantas, R. N., Oshiro, C. A., Nomura, C. H., Bor‐Seng‐Shu, E., Oliveira, M. D. L., Leite, C. D. C., Martin, M. D. G. M., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1082275 · Cited by 13
Ersbøll, A. K., Kristensen, M. S., Nybo, M., Hede, S. M., Mikkelsen, K. H., Gislason, G., Larsen, M. L., & Green, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286376 · Cited by 11
Ye, X., Wang, S., Liu, X., Wu, Q., Lv, Y., Lv, Q., Li, J., Li, L., & Yang, Y. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074067 · Cited by 11
Sato, R., Matsuzawa, Y., Yoshii, T., Akiyama, E., Konishi, M., Nakahashi, H., Minamimoto, Y., Kimura, Y., Okada, K., Maejima, N., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64368 · Cited by 11
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 14
“More recently, monoclonal antibody and small interfering RNA strategies to inhibit PCSK9 have demonstrated powerful effects on serum LDL cholesterol [26,27], with a reduction in major adverse cardiovascular events (MACE) in those with established CAD on monoclonal antibody strategies [26,28].”
BackgroundPharmacotherapy and revascularization strategies of peripheral artery disease
Moras, E., Khan, M. I., Song, D. D., Syed, M., Prabhakaran, S. Y., Gandhi, K., Lavie, C. J., Alam, M., Sharma, R. M., & Krittanawong, C. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102430 · Cited by 13
Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Dankar, R., Wehbi, J., & Refaat, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040461 · Cited by 11
“Similarly, the ODYSSEY OUTCOMES trial studied the effect of alirocumab on cardio-vascular events [11].”
MethodLeiter, L. A., Hegele, R. A., Brown, V., Bergeron, J., Mackinnon, E. S., & Mancini, G. B. J. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2505190 · Cited by 12
“Recent analyses of large PCSK9i trials have identified subsets of patients with established ASCVD who are at increased risk of CV events and would derive the largest absolute benefit from LLT intensification with PCSK9i therapy [16,17].”
BackgroundChen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
“The trial compared treatments in patients who experienced ACS in 1 to 12 months (median 2.6) before randomization [60].”
InfluentialEl colesterol LDL como agente causal de la aterosclerosis
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.001 · Cited by 16
Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Vroom, M. M., & Dodart, J. (2024) · Vaccines · doi:10.3390/vaccines12090973 · Cited by 13
Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome
Giordano, S. A., Ielapi, J., Salerno, N., Cersosimo, A., Lucchino, A., Laschera, A., Canino, G., Costanzo, A. D., Rosa, S. D., Torella, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2510374 · Cited by 11
“…excluded patients who suffered from an MI 4 weeks (i.e., the FOURIER (further cardiovascular outcomes research with PCK9I in patients with elevated risk) [67] and the ODYSSEY outcomes (evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab) [68]).”
BackgroundStatin-Associated Muscle Symptoms: Identification and Recommendations for Management
Maki, K. C., Kirkpatrick, C. F., Cheeley, M. K., & Jacobson, T. A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01246-y · Cited by 12
Li, X., Liu, Y., Wang, J., Chen, X., Reichetzeder, C., Elitok, S., Krämer, B. K., Doebis, C., Huesker, K., von Baehr, V., et al. (2024) · Nutrients · doi:10.3390/nu16223936 · Cited by 16
Li, C., Wang, W., Ma, S., Lo, L., Wu, C., Chang, W., Chen, Y., & Chen, T. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae438 · Cited by 11
Lolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 21
Prescriber Uptake and Use of Novel Lipid‐Lowering Therapies
Hwang, J., Peterson, E. D., Gupta, A., Decicco, E., Sarnes, E., & Návar, A. M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040768 · Cited by 11
Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis
Rodrigo-Alaíz, Á., Corral-Gudino, L., de Isla, L. P., Pardo, H. G., Calle, D. G., & Miramontes‐González, J. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124163 · Cited by 18
“Now, the arrival of inclisiran further improves the therapeutic arsenal [6,7].”
HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications
Stoicescu, C. I., Văcărescu, C., & Cozma, D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144945 · Cited by 17
“Despite their high cost, these agents are effective tools for minimizing sdLDL burden in select high-risk patients [51,52].”
The Effect of Lipid-Lowering Therapy on Coronary Artery Plaque in East Asia Population
Fujisaki, T., Shirahama, Y., Sheng, F., Ikeda, K., Osada, N., Tanaka, S., Zhang, Y., & Tsujita, K. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.05.016 · Cited by 10
A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice
Knickelbine, T., Jia, L., White, S., Garberich, R., Oberembt, S., Wills, S., Miedema, M. D., & Brilakis, E. S. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.005 · Cited by 10
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 12
Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease
Catapano, A. L., Tokgözoğlu, L. S., Silva, A. M. E., & Bruckert, É. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100002 · Cited by 11
Intensive Lipid Lowering in Elderly Patients
Gotto, A. M. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2333 · Cited by 10
Zijlstra, L. E., Trompet, S., Mooijaart, S. P., van Buren, M., & Jukema, J. W. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.11.010 · Cited by 10
Self-citationLipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 11
McCormick, D., Bhatt, D. L., Bays, H. E., Taub, P. R., Caldwell, K. A., Guerin, C. K., Steinhoff, J. P., Ahmad, Z., Singh, R. M., Moreo, K., et al. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1517 · Cited by 11
Self-citationLipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
Temporelli, P. L., Arca, M., D’Erasmo, L., & Caterina, R. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040886 · Cited by 10
“They also dissipate lingering doubts about the possibility that cholesterol lowering is linked to an increase in hemorrhagic stroke, which did not appear despite the extremely low levels of both LDL and total cholesterol achieved in the three above-mentioned PCSK9 inhibitor trials [19,20,51,53,54].”
BackgroundMethodResultInfluentialMinno, A. D., Orsini, R. C., Chiesa, M., Cavalca, V., Calcaterra, I. L., Tripaldella, M., Anesi, A., Fiorelli, S., Eligini, S., Colombo, G. I., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081073 · Cited by 11
“In these cases, clinical studies have shown that the use of two fully human PCSK9i, Evolocumab and Alirocumab, resulted in a significant reduction in LDL-C levels and atherosclerotic plaque regression [21,22].”
BackgroundAnesi, A., Minno, A. D., Calcaterra, I. L., Cavalca, V., Tripaldella, M., Porro, B., & Minno, M. N. D. D. (2021) · Biomedicines · doi:10.3390/biomedicines9121941 · Cited by 12
Yang, S., Shen, W., Zhang, H., Wang, C., Yang, P., & Wu, Q. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07338-8 · Cited by 14
“In our research, the negative results about evaluating the effect of PCSK9 mAbs in lowering the incidence of cardiovascular death were broadly consistent with the FOURIER trial and the ODYSSEY OUTCOMES trial [18, 30].”
BackgroundResultShah, N. N., Ghazi, L., Yamamoto, Y., Martin, M. C., Simonov, M., Riello, R. J., Faridi, K. F., Ahmad, T. A., Wilson, F. P., & Desai, N. R. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.07.002 · Cited by 11
Cao, J., Zhang, L., Ma, L., et al. (2022) · PeerJ · doi:10.7717/peerj.14078 · Cited by 10
“The decrease of its value can benefit from the decrease of atherosclerotic cardiovascular endpoint (Yangjie, Kun & Xiufang, 2021; Schwartz et al., 2018).”
BackgroundAssociation of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudsø, L. C., Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4798 · Cited by 10
Cardiotoxicity as a Possible Side Effect of Statins
Chaulin, A. M. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401022 · Cited by 12
Sakhuja, S., Bittner, V., Brown, T. M., Farkouh, M. E., Levitan, E. B., Safford, M. M., Woodward, M., Chen, L., Sun, R., Dhalwani, N. N., et al. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07452-1 · Cited by 13
“Randomized controlled trials have demonstrated that ezetimibe and PCSK9i are effective in reducing the risk for recurrent ASCVD events in adults taking a statin [15–17].”
Self-citationThe Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 14
Preventive Therapies in Peripheral Arterial Disease
Shah, A. J., Pavlatos, N., & Kalra, D. K. (2023) · Biomedicines · doi:10.3390/biomedicines11123157 · Cited by 13
“However, investigators in the original trial did not report segregated data on PAD outcomes or complications [87].”
BackgroundNonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 15
“8,12,18,19 There is also biological plausibility for ASCVD risk-reduction benefi t with bempedoic acid-ezetimibe combination therapy and inclisiran, though these therapies lack outcome data currently.”
BackgroundLin, L., Yu, H., Xue, Y., Wang, L., & Zhu, P. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01826-6 · Cited by 10
“Alirocumab and Evolocumab are clinically applied PCSK9 inhibitors known for their effective lipid-lowering effects and reliable safety profiles [10, 11].”
BackgroundIcosapent Ethyl for Hypertriglyceridemia: Insights From the REDUCE-IT Trial
Miller, M. J. (2019) · Future Cardiology · doi:10.2217/fca-2019-0054 · Cited by 10
(Summary of the recommendations for long-term secondary prevention after myocardial infarction)
Ošťádal, P., Táborský, M., Linhart, A., Vrablík, M., Češka, R., Cífková, R., Králíková, E., Adámková, V., Kvapil, M., & Jojko, Z. (2019) · Cor et Vasa · doi:10.33678/cor.2019.064 · Cited by 11
Munkhaugen, J., Sverre, E., Peersen, K., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320923187 · Cited by 10
Choi, I. J., Lim, S., Lee, D., Lee, W. J., Lee, K. Y., Kim, M., & Jeon, D. S. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.032 · Cited by 11
Lucki, M., Chlebuś, E., Wareńczak, A., & Lisiński, P. (2021) · Medicina · doi:10.3390/medicina57030190 · Cited by 11
“b7302 Lipid metabolism [29] LDL-C (mg/dL) >116 115–71 70–55 <55 ISCHEMIC STROKE 51.”
Kubica, J., Podhajski, P., Magielski, P., Kubica, A., Adamski, P., Junik, R., Pinkas, J., & Navarese, E. P. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0148 · Cited by 12
Langslet, G., Holven, K. B., & Bogsrud, M. P. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab228 · Cited by 9
Palacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.07.021 · Cited by 12
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
The Potential Clinical Benefit of Lowering Lipoprotein(a)
Ference, B. A. (2022) · JAMA · doi:10.1001/jama.2022.5333 · Cited by 11
The DA VINCI study: is Ireland achieving ESC/EAS guideline–directed LDL-C goals?
Offiah, G., O'Connor, C. T., Kennedy, C., Gallagher, J., O’Connor, P. A., McAdam, B. F., Ray, K. K., Schoonen, M., & Maher, V. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03050-6 · Cited by 11
“With the emergence of PCSK9is, which reduce LDL-C levels by 50–60%, these benefits continue due to additional reductions in LDL-C concentration [7, 8].”
BackgroundSabouret, P. F., Puymirat, É., Kownator, S., ABDENNBI, K., LEBEAU, F., MELTZ, M., Angoulvant, D., & Schiele, F. (2022) · Panminerva Medica · doi:10.23736/s0031-0808.22.04777-2 · Cited by 12
Bowman, L. J., Weidinger, F. F., Albert, M. A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac633 · Cited by 10
“The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibiting monoclonal antibodies (evolocumab and alirocumab) provide a recent example of such a strategy failing patients.(11,12) These agents have an impressive LDL cholesterol-lowering effect and, in large phase 3 randomized trials, were clearly shown to safe…”
BackgroundSelf-citationTsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 10
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 12
Doggrell, S. A. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1609942 · Cited by 11
“The monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9), such as evolocumab and alirocumab, reduce LDL cholesterol levels to a greater extent than the statins, increase HDL cholesterol levels and lower triglyceride levels [39,40].”
BackgroundStatus of PCSK9 Monoclonal Antibodies in Australia
Scherer, D. J., Nelson, A. J., O’Brien, R. C., Kostner, K., Hare, D. L., Colquhoun, D. M., Barter, P. J., Aylward, P. E., Nicholls, S. J., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.04.014 · Cited by 11
Hurt‐Camejo, E. (2020) · Journal of Lipid Research · doi:10.1194/jlr.c120000650 · Cited by 11
Desjobert, E., Tea, V., Schiele, F., Ferrières, J., Simon, T., Danchin, N., & Puymirat, É. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.06.003 · Cited by 10
Kraler, S. C., Liberale, L., Tirandi, A., Moriero, M., Wang, Y., Farag, M., Carbone, F., Bertolotto, M. B., Pusterla, V., Ramoni, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf979 · Cited by 12
“16 Almost simultaneously, based on experimental and clinical data, 17–19 the CANTOS and subsequently the COLCOT and LoDoCo trials showed that anti-inflammatory remedies acting downstream of the NLRP3 inflammasome provided additional clinical benefit.”
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 14
“11,12 Additionally, antisense oligonucleotide (ASO) therapies and small interfering RNA (siRNA) molecules have been developed to inhibit PCSK9 or apoli-poprotein synthesis to improve dyslipidaemia.”
InfluentialAttainment of Lipid Targets Following Coronary Artery Bypass Graft Surgery: Can We Do Better?
Lan, N. S. R., Ali, U., Yeap, B. B., Fegan, P. G., Larbalestier, R. I., & Bell, D. A. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.187 · Cited by 10
Mahmood, T., Miles, J. R., Minnier, J., Tavori, H., DeBarber, A. E., Fazio, S., & Shapiro, M. D. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.10.009 · Cited by 9
Justino, G. B., Justino, L. B., Müller, M. E., Rocha, A. V., Mazetto, A. B., Cardoso, R. N., & Leucker, T. M. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.10.043 · Cited by 12
Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Wang, L., Wang, S., Song, C., Yu, Y., Jiang, Y., Wang, Y., & Li, X. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00478-z · Cited by 12
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 18
Kim, H., Ahn, J., Kang, D., Lee, J., Choi, Y., Park, S., & Park, D. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.04.001 · Cited by 21
Vivas, D., Escobar, C., Cordero, A., Fernández-Olmo, R., Oterino, A., Blanco-Echevarría, A., Botana, M., Escribano, D., Freijo, M. D. M., Losas, P. M., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.06.002 · Cited by 16
Dai, Y., Sheng, Y., Zheng, Z., & Di, W. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132435 · Cited by 10
Seijas‐Amigo, J., Mauriz-Montero, M. J., Suárez‐Artime, P., Gayoso-Rey, M., Reyes-Santías, F., Estany‐Gestal, A., Casas-Martínez, A., González-Freire, L., Rodríguez-Vázquez, A., Pérez-Rodriguez, N., et al. (2024) · Diseases · doi:10.3390/diseases12100244 · Cited by 9
Li, W., Wu, C., Li, W., & Li, L. (2025) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108224 · Cited by 11
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 14
CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis
Gu, B., Li, M., Li, D., & Huang, K. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10587-7 · Cited by 16
“Based on these findings, PCSK9 inhibitors, such as Evolocumab and Alirocumab, have been approved for clinical use, demonstrating the effectiveness of targeting PCSK9 as a therapeutic strategy [2, 9].”
InfluentialJha, M., Agrawal, S. P., Maheta, D., Bhattacharjee, P., Jain, H., Zacks, J. S., Frishman, W. H., & Aronow, W. S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2511063 · Cited by 11
“PCSK9 inhibitors have also been shown to reduce the likelihood of major adverse cardiovascular events (MACE) among ) [51,52].”
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 12
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“176,177 In patients with a recent acute coronary syndrome on optimal statin therapy, ali-rocumab improved CV outcomes in patients with baseline LDL-C ≥ 100 mg/dL. 178 With respect to body weight, PCSK9 inhibitors are considered weight-neutral, with no evidence of weight loss or gain in randomized…”
EGF-A peptides: A promising strategy for PCSK9 inhibition
Cariou, B., & Dijk, W. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.010 · Cited by 10
Mehta, A., Mahtta, D., Gulati, M., Sperling, L. S., Blumenthal, R. S., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0822-6 · Cited by 10
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2020) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2020.1742455 · Cited by 8
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

